GlassScriptPhysician profile
Sara Niego
NPI 1730193814
$25,165.18
in general payments reported to CMS, 2019-2025
40 companies · $3,979 in 2025
The $3,979 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,622 · 2021: $4,410 · 2022: $4,748 · 2023: $4,927 · 2024: $4,479 · 2025: $3,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,172.72 |
| Education | $212.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,307.53 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,619.56 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,134.49 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $2,051.66 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $1,945.87 | 2020-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $1,491.24 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,319.81 | 2020-2025 | Ingrezza |
| Alkermes, INC. | $1,240.80 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $868.05 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $863.79 | 2020-2025 | Fanapt, Hetlioz |
| Indivior INC. | $857.34 | 2020-2025 | Sublocade, Perseris |
| Eisai INC. | $656.71 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $599.54 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $518.29 | 2021-2022 | |
| Allergan, INC. | $460.63 | 2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $409.23 | 2020-2023 | Wakix |
| Axsome Therapeutics, INC. | $407.51 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $387.18 | 2020-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Tris Pharma INC | $376.29 | 2022-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $359.67 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $353.16 | 2021-2025 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $341.37 | 2020-2022 | |
| Almatica Pharma LLC | $225.73 | 2021-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $208.73 | 2022-2025 | Qelbree, Qelbree |
| Orexo US, INC. | $195.68 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $181.58 | 2022-2024 | Quviviq |
| Braeburn INC. | $176.03 | 2024-2025 | Brixadi |
| Merck Sharp & Dohme LLC | $89.71 | 2020-2023 | Belsomra |
| Neos Therapeutics, LP | $89.07 | 2023-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $83.16 | 2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $79.36 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $56.36 | 2021 | |
| Tempus Ai, INC | $48.73 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.22 | 2025 | Rejoyn |
| Avion Pharmaceuticals | $29.50 | 2023 | Methylphenidate Hydrochloride |
| Luye Pharma (USA) LTD. | $23.33 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $18.98 | 2020 | |
| Uswm, LLC | $18.79 | 2024 | Lucemyra |
| Arbor Pharmaceuticals, INC. | $18.19 | 2020 | |
| Neuronetics, INC. | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Niego listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.